Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 5Ovarian Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Neoplasms 3Stomach Neoplasms 2Retinoblastoma 2Neoplasms 2Uterine Cervical Neoplasms 1Squamous-Cell Lung Cancer 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1NSCLC 1Lymphatic Metastasis 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Carcinoma 1

Interventions

Pemetrexed 9Drug Therapy 9osimertinib 7Radiotherapy 6Carboplatin 6anlotinib 5Radiosurgery 5aflutinib 4Gefitinib 4Docetaxel 4Cisplatin 4tislelizumab 3pembrolizumab 3icotinib 3Vinorelbine 3Paclitaxel 3Gemcitabine 3Erlotinib Hydrochloride 3toripalimab 2dacomitinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Liquid Biopsy 2Immune Checkpoint Inhibitors 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × NSCLC × Platinum Compounds × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡